An AACR Special Conference on
Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications
October 3-6, 2013 • The Manchester Grand Hyatt, San Diego, CA

Thursday, October 3

6:30 p.m.-8:00 p.m.  Welcome and Opening Keynote Talks
Session Co-Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
Douglas B and C

6:30 p.m.-7:15 p.m.  Breast cancer genomics: Implications for individuals and populations
Charles M. Perou, University of North Carolina, Chapel Hill, NC

7:15 p.m.-8:00 p.m.  Tumor plasticity and reactive stroma in breast cancer metastasis
Yibin Kang, Princeton University, Princeton, NJ

8:00 p.m.-9:30 p.m.  Opening Reception
Douglas D
7:30 a.m.-8:30 a.m.  Continental Breakfast  
Douglas BC Foyer

8:30 a.m.-10:30 a.m.  Session 1: Genomics/Epigenomics/“Omics”  
Session Chairperson: Charles M. Perou, University of North Carolina, Chapel Hill, NC  
Douglas B and C

8:30 a.m.-9:00 a.m.  Clonal evolution and breast cancer subtypes  
Samuel Aparicio, BC Cancer Research Center, Vancouver, BC, Canada

9:00 a.m.-9:30 a.m.  Genomic studies of breast cancer progression  
Elaine R. Mardis, Washington University School of Medicine, St. Louis, MO

9:30 a.m.-10:00 a.m.  Understanding estrogen receptor transcription in breast cancer  
Jason S. Carroll, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

10:00 a.m.-10:30 a.m.  Protein pathway activation mapping for personalized breast cancer therapy  
Emanuel F. Petricoin, III, George Mason University, Manassas, VA

10:30 a.m.-11:00 a.m.  Break  
Douglas Foyer East
11:00 a.m.-12:45 p.m.  Session 2: Breast Cancer Models
Session Chairperson: Alana L. Welm, Huntsman Cancer Institute, Salt Lake City, UT
Douglas B and C

11:00 a.m.-11:30 a.m.  Breast tumor grafts as preclinical models for anti-metastasis therapy
Alana L. Welm

11:30 a.m.-12:00 p.m.  Studying therapy response and resistance in mouse models of breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

12:00 p.m.-12:30 p.m.  Targeting tumor-initiating cells in xenograft models of human breast cancer
Michael T. Lewis, Baylor College of Medicine Cancer Center, Houston, TX

12:30 p.m.-12:45 p.m.  Loss of the hippo pathway scaffold “Kibra” in a mouse model of human claudin-low breast cancer*
Jennifer F. Knight, McGill University Goodman Cancer Research Centre, Montreal, QC, Canada

12:45 p.m.-1:00 p.m.  Genomic rearrangements and promoter demethylation drive therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer*
Petra ter Brugge, Netherlands Cancer Institute, Amsterdam, The Netherlands

1:00 p.m.-3:30 p.m.  Poster Session A/Lunch
Douglas D/Douglas D Foyer

*Short talks from proffered papers
3:45 p.m.-5:45 p.m.  Session 3: Stem Cells/Mammary Lineage Tracing
Session Chairperson: Jane E. Visvader, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
Douglas B and C

3:45 p.m.-4:15 p.m.  Using lineage tracing and clonal analysis to unravel mammary gland expansion and cancer initiation
Alexandra Van Keymeulen, Université Libre de Bruxelles, Brussels, Belgium

4:15 p.m.-4:45 p.m.  Dissecting cancer through the lens of development
Geoffrey M. Wahl, The Salk Institute, La Jolla, CA

4:45 p.m.-5:15 p.m.  Mammary epithelial subtypes and their implications for breast cancer
Jane E. Visvader

5:15 p.m.-5:45 p.m.  Wnt and Fgf signaling in mammary stem cells and breast cancer
Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
Saturday, October 5

7:30 a.m.-8:30 a.m.  Continental Breakfast  
Douglas BC Foyer

8:30 a.m.-10:30 a.m.  Session 4: Tumor Dormancy and Metastasis  
Session Chairperson: Lewis A. Chodosh, University of Pennsylvania, Philadelphia, PA  
Douglas B and C

8:30 a.m.-9:00 a.m.  Assembly and function of the tumor microenvironment of metastasis in breast tumors  
John S. Condeelis, Sr., Albert Einstein College of Medicine, Bronx, NY

9:00 a.m.-9:30 a.m.  Biology and clinical implications of circulating tumor cells and bone marrow micrometastasis  
Klaus Pantel, University Medical Center, Hamburg, Germany

9:30 a.m.-10:00 a.m.  Mechanisms of breast cancer dormancy and recurrence  
Lewis A. Chodosh

10:00 a.m.-10:15 a.m.  The role of syndecan-1 in breast cancer metastasis to the brain*  
Melvin Moore, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

10:15 a.m.-10:30 a.m.  The Six2 homeoprotein mediates breast cancer metastasis via repressing E-cadherin*  
Chu-An Wang, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO

10:30 a.m.-11:00 a.m.  Break  
Douglas Foyer East

*Short talks from proffered papers
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Presenter/Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m.-12:30 p.m.</td>
<td><strong>Session 5: Targeted Therapies I</strong>&lt;br&gt;<strong>Session Chairperson:</strong> Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN</td>
<td>Douglas B and C</td>
</tr>
<tr>
<td>11:00 a.m.-11:30 a.m.</td>
<td><strong>Targeting downstream effectors of growth factor signaling</strong>&lt;br&gt;Douglas Yee</td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.-12:00 p.m.</td>
<td><strong>Targeting the androgen receptor in multiple breast cancer subtypes</strong>&lt;br&gt;Jennifer K. Richer, University of Colorado Anschutz Medical Campus, Aurora, CO</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.-12:30 p.m.</td>
<td><strong>Exploiting DNA repair deficiencies in breast cancer using PARP inhibitors</strong>&lt;br&gt;Andrew Tutt, King’s College London, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.-2:45 p.m.</td>
<td><strong>Free Time/Lunch on Own</strong></td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:45 p.m.</td>
<td><strong>Session 6: Targeted Therapies II</strong>&lt;br&gt;<strong>Session Chairperson:</strong> Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN</td>
<td>Douglas B and C</td>
</tr>
<tr>
<td>2:45 p.m.-3:15 p.m.</td>
<td><strong>Harnessing mTOR and translational control for the clinic</strong>&lt;br&gt;Robert J. Schneider, New York University School of Medicine, New York, NY</td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.-3:45 p.m.</td>
<td><strong>Translating genetic screens into new therapeutic strategies</strong>&lt;br&gt;Thomas (Trey) F. Westbrook, Baylor College of Medicine, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>3:45 p.m.-4:15 p.m.</td>
<td><strong>Rationale and current status of development of PI3K/TOR pathway inhibitors</strong>&lt;br&gt;Carlos L. Arteaga</td>
<td></td>
</tr>
<tr>
<td>4:15 p.m.-4:30 p.m.</td>
<td><strong>P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling</strong>&lt;br&gt;Lloye M. Dillon, Geisel School of Medicine at Dartmouth, Lebanon, NH</td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.-4:45 p.m.</td>
<td><strong>Overcoming resistance to PI3K inhibitors in breast cancer: Results of a pooled shRNA screen and combinatorial drug screen</strong>&lt;br&gt;Sadhna Vora, Massachusetts General Hospital, Boston, MA</td>
<td></td>
</tr>
</tbody>
</table>
Sunday, October 6

7:30 a.m.-8:30 a.m.  Continental Breakfast  
Douglas BC Foyer

8:30 a.m.-9:30 a.m.  Session 7: Hot Topics/Late-Breaking Research  
Session Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX  
Douglas B and C

  8:30 a.m.-9:00 a.m.  Molecular and clinical impact of APOBEC3B mutagenesis in breast cancer  
Reuben S. Harris, University of Minnesota, Minneapolis, MN

  9:00 a.m.-9:15 a.m.  Integrative functional genomics of breast cancer*  
Richard Marcotte, Ontario Cancer Institute, Toronto, ON, Canada

  9:15 a.m.-9:30 a.m.  Plk2 regulates mitotic spindle orientation and mammary gland development*  
Elizabeth Villegas, Baylor College of Medicine, Houston, TX

9:30 a.m.-9:45 a.m.  Break  
Douglas Foyer East

*Short talks from proffered papers
9:45 a.m.-11:45 a.m.  Session 8: Tumor Microenvironment and Immunity
Session Chairperson: Zena Werb, UCSF Helen Diller Family
Comprehensive Cancer Center, San Francisco, CA
Douglas B and C

9:45 a.m.-10:15 a.m.  How tumors regulate their microenvironment in primary sites
and metastasis
Zena Werb

10:15 a.m.-10:45 a.m.  Tissue tension engages developmental programs to promote
tumor progression
Valerie M. Weaver, University of California Medical Center, San
Francisco, CA

10:45 a.m.-11:15 a.m.  Stroma-targeted immunotherapy
Stephen Gottschalk, Texas Children’s Cancer and Hematology
Centers, Houston, TX

11:15 a.m.-11:45 a.m.  Immunomodulation of breast cancer
Mary (Nora) L. Disis, University of Washington, Seattle, WA

11:45 a.m.-12:00 p.m.  Closing Remarks and Departure
Douglas B and C